SCHEMBL4357285

SCHEMBL4357285

CC(=O)Nc1ccc(-c2ccc3ncnc(N4CCN(c5ccc(C)cc5)CC4)c3c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.53
BACE1 P56817 1/20 0.53
CLK4 Q9HAZ1 7/20 0.53
CYP3A4 P08684 7/20 0.53
HIF1A Q16665 4/20 0.53
PDGFRB P09619 5/20 0.52
HSD17B10 Q99714 3/20 0.52
LMNA P02545 3/20 0.52
MAPK1 P28482 3/20 0.52
CYP2D6 P10635 3/20 0.52
TSHR P16473 2/20 0.52
MAPKAPK2 P49137 1/20 0.52
USP2 O75604 3/20 0.49
AKT1 P31749 1/20 0.49
CYP1A2 P05177 6/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
ALDH1A1 P00352 4/20 0.48
MAPT P10636 3/20 0.47
KDM4E B2RXH2 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4362417 0.87 CYP3A4 (0.68) CLK4CYP3A4HIF1APDGFRBHSD17B10
SCHEMBL4355005 0.86 CLK4 (0.69) CLK4CYP3A4HIF1AHSD17B10LMNA
SCHEMBL4356104 0.86 ACHE (0.56) ACHEBACE1CLK4CYP3A4HIF1A
SCHEMBL4358121 0.86 CLK4 (0.54) ACHECLK4CYP3A4HIF1APDGFRB
SCHEMBL4357572 0.84 PIK3CA (0.52) CYP3A4HSD17B10LMNAMAPK1MAPKAPK2
SCHEMBL4361955 0.84 HRH4 (0.52) CYP3A4MAPKAPK2CYP1A2MEN1KMT2A
SCHEMBL4358134 0.82 ACHE (0.61) ACHEBACE1CLK4CYP3A4HIF1A
SCHEMBL4363813 0.82 ACHE (0.59) ACHEBACE1CLK4CYP3A4HIF1A
SCHEMBL4362468 0.82 PDGFRB (0.62) PDGFRBMAP4K4
SCHEMBL4885395 0.79 MAPK1 (0.64) CLK4CYP3A4HSD17B10LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US claimed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 US disclosed
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2021-01-05 US disclosed
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2016-09-08 US disclosed
US-9259426-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2016-02-16 US disclosed
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR4A1 ACHE 4515/4885BACE1 4342/4885CLK4 957/4885
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR5A2, NR4A1 ACHE 4468/4885BACE1 4089/4885CLK4 960/4885
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR5A2 ACHE 4535/4885BACE1 4232/4885CLK4 1192/4885
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR5A2 ACHE 4535/4885BACE1 4232/4885CLK4 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.